Exelixis | EXEL - Vertriebs- Und Verwaltungskosten





Vertriebs- Und Verwaltungskosten Veränderung Datum
Acadia Pharmaceuticals USD 148.57M 12.22M 2026-06
Agios Pharmaceuticals USD 38.46M 4.51M 2026-03
Akebia Therapeutics USD 23.53M 3.19M 2025-12
Amgen USD 1.72B 134M 2026-06
AstraZeneca USD 5.8B 735M 2026-06
Bayer EUR 3.96B 267M 2026-06
BioMarin Pharmaceutical USD 395.55M 137.27M 2026-06
Bristol-Myers Squibb USD 1.83B 209M 2026-06
Cytokinetics USD 104.4M 499K 2026-06
Eisai JPY 114.83B 4.71B 2026-06
Eli Lilly USD 3.43B 496M 2026-06
Exelixis USD 147.63M 8.03M 2026-06
Genmab DKK 205M 39M 2026-06
Glaxosmithkline GBP 2.12B 1.44B 2026-03
Incyte USD 351.73M 23.64M 2026-06
Ionis Pharmaceuticals USD 130.07M 20.92M 2026-06
MacroGenics USD 9.71M 1.77M 2026-03
Merck USD 2.89B 219M 2026-06
Moderna USD 216M 43M 2026-06
Nektar Therapeutics USD 11.87M 1.7M 2026-03
Neurocrine Biosciences USD 383.1M 64.6M 2026-06
Novartis USD 3.24B 101M 2026-06
Pfizer USD 3.41B 496M 2026-06
Puma Biotechnology USD 16.82M 8.15M 2024-09
Sanofi EUR 2.49B 252M 2026-03
Takeda JPY 286.51B 5.48B 2026-06
Ultragenyx Pharmaceutical USD 88M 1000K 2026-03
Xencor USD 77.54M 4.59M 2026-06